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Community-acquired pneumonia (CAP) is a leading cause of death in both the developed and developing world.
The very young and elderly are especially vulnerable. Even with appropriate early antibiotics we still have not
improved the outcomes in these patients since the 1950s, with 30-day case fatality rates of between 10–12%.
Interventions to improve outcomes include immunomodulatory agents such as macrolides and corticosteroids.
Treating doctors identify CAP patients who are likely to have poor outcomes by using severity scores such as the
pneumonia severity index and CURB-65, which allows these patients to be placed in ICU settings from the start
of the admission. Another novel way to identify these patients is with the use of biomarkers. This review illustrates how
various biomarkers have been shown to predict mortality, complications and response to treatment in CAP patients.
The evidence using either procalcitonin or C-reactive protein to demonstrate response to treatment and hence that
the antibiotics chosen are appropriate can play an important role in antibiotic stewardship.
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The first description of pneumonia has been credited to
Hippocrates, and in the 2500 years following his account
we have accumulated vast knowledge and understanding
of Osler’s “Captain of the Men of Death”. Community-
acquired pneumonia (CAP) is, however, still a leading
cause of death in the developed and developing world.
Whilst treatment options and diagnostic techniques
have improved, overall 30-day mortality for CAP is still
10–12.1% [1, 2], and researchers continue to try to find
methods to improve outcomes. One of these approaches
is the use of biomarkers and there is a growing body of
evidence to suggest that biomarkers could help with this
challenge. There are many excellent biomarker review
articles available; this review hopes to add to the literature
with some recent practical data [3–6].
Biological markers, more commonly called biomarkers,
were (as recently as 1998) defined by the National Institutes
of Health Biomarkers Definitions Working Group, as
“a characteristic that is objectively measured andCorrespondence: ericashaddock@gmail.com
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pathogenic processes, or pharmacologic responses to a
therapeutic intervention” [7]. Numerous biomarkers have
been tested and validated for use in CAP. This review will
be examining recent evidence and how biomarkers may
be of use in daily practice.
Traditional biomarkers such as white cell count (WCC)
and erythrocyte sedimentary rate (ESR) have become less
relied upon due to their lower sensitivity and specificity
compared to the more promising C-reactive protein
(CRP) and procalcitonin (PCT), which are currently in
widespread use. Other inflammatory mediators such as
interleukin (IL)-1β, IL-6, tumor necrosis factor (TNF)-α,
and IL-8, have also been found to be elevated in response
to the infection. Unfortunately these pro-inflammatory
cytokines have very short half-lives and lack specificity;
therefore, they are not currently viewed as good pros-
pective biomarkers [3].Basic science
The biomarkers that have been the most thoroughly
validated in CAP and that are accessible to most medical
practitioners are CRP and PCT.
CRP is secreted from hepatic cells in response to
elevated IL-6, IL-1β, and TNF-α. These cytokines arele is distributed under the terms of the Creative Commons Attribution 4.0
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various innate inflammatory cells when they encounter
pathogen-associated molecular patterns (PAMPS) from
invading organisms. Additional sources of CRP synthesis
have been recently identified and include lymphocytes,
monocytes, neurons, and atherosclerotic plaques [8].
CRP’s name originates from its ability to precipitate C-
polysaccharide of Streptococcus pneumonia, and it was
one of the first acute phase proteins to be described.
Due to the main production of CRP occurring in the
liver, it is important to remember it is not a reliable
marker for sepsis in patients with liver failure. CRP syn-
thesis starts very rapidly after a single stimulus: serum
concentrations rise within about 6 h and peak around
48 h. The plasma half-life of CRP is about 19 h, which is
constant in health and disease. Therefore, the main de-
terminant of plasma CRP concentration is the synthesis
rate, which directly reflects the degree of the patho-
logical process stimulating CRP production [8].
PCT is a 116 amino acid peptide, with a molecular
weight of 14.5 kDa. It belongs to the calcitonin super-
family of peptides, and is a precursor to calcitonin pro-
duction usually taking place in the C cells of the thyroid
gland [9]. PCT synthesis is very interesting and occurs in a
tissue-specific manner. If there is no infection, transcription
of the CALC-1 gene for PCT in the non-neuroendocrine
tissue is suppressed, except in the C cells of the thyroid
gland. A microbial infection induces a substantial increase
of CALC-1 gene expression in all parenchymal tissue and
differentiated cell types in the body that produce PCT. We
are currently uncertain of the exact function of PCT syn-
thesised in the non-neuroendocrine tissues under microbial
infection [9]. PCT is detectable within 2–4 h of infection,
peaks within 6–24 h, and can be present for up to 7 days.
The half-life is 22–26 h in plasma and it is cleared mainly
through proteolysis with minimal renal excretion [10]. The
response to antibiotics can also be monitored well with
PCT; as a “rule of thumb”, a decline of > 30% per day indi-
cates improvement of systemic inflammation. This decrease
is due to the natural plasma disappearance rate of PCT
if no further inflammatory activation is occurring [11].
Interferon-gamma (IFN-γ), an important mediator in
viral infections, down-regulates PCT production, making
PCT a very useful test to help distinguish between viral
and bacterial infections.
Diagnosis
Biomarkers are helpful in aiding with the initial diagno-
sis of CAP. In many patients, making the diagnosis of
CAP is straightforward: a history is taken, followed by
examination and then a chest X-ray to confirm the diag-
nosis. However, in some patients there might be co-
morbidities or the picture might not be typical, which
makes it more difficult for the clinician to make aconfident diagnosis. As the world’s population ages and
the number of patients on therapeutic immunosuppres-
sion increases, the differential diagnoses for patients
with dyspnea and cough increases. This diagnosis list in-
cludes cardiac failure, an acute exacerbation of chronic
obstructive pulmonary disease, atypical pneumonia, pul-
monary embolism or even interstitial lung disease. This
is the place where biomarkers can aid in diagnosis.
Müller et al. [12] demonstrated a significant improvement
in diagnostic accuracy when adding PCT and CRP to
standard clinical signs and symptoms. These biomarkers
also performed better than standard makers of infection
such as white cell count and raised temperature in different
settings, including primary care and the emergency room,
as well as in bacteriaemic and non-bacteraemic patients
(Fig. 1 [12, 13]). The area under the curve (AUC) of clinical
signs and symptoms alone was 0.79 (95% CI 0.75–0.83);
with added PCT and highly sensitive CRP it was 0.92
(95% CI 0.89–0.94; p < 0.001) [12].
Response to treatment and antibiotic stewardship
Biomarkers can be monitored to evaluate response to
treatment, which can impact length of antibiotic use and
predict outcomes. A paper by Coelho et al. [14] adds a
new dimension to the basic blood test C-reactive protein
(CRP), showing its use to predict outcomes. In patients
with severe CAP, they found that a CRP ratio comparing
day 5 (D5) CRP against admission CRP predicted ICU
outcome, using receiver operating characteristic (ROC)
curves with a value of 0.73 (95% CI 0.64–0.82). This pro-
spective observational cohort study classified CAP pa-
tients into the following groups: fast response—when D5
CRP was ≤ 0.4 of day 1 (D1) CRP concentration; slow
response—when D5 CRP > 0.4 and D7 ≤ 0.8 of D1 CRP
concentration; and non-response—when D7 CRP was > 0.8
of D1 CRP concentration. The group then performed com-
parisons between survivors and non-survivors using
standard statistical analysis. When these groups were
analysed for ICU survival, mortality was as follows:
4.6% in fast response patients, 17.3% in slow response,
and 36.4% in non-response patients (p < 0.001). Hospital
mortality showed a similar pattern. If clinicians were to
use biomarkers in this fashion they could identify patients
who are ready for discharge, those who have shown a fast
response to treatment versus those patients who might
not have adequate source control or resistant organisms;
that is, those with slow or no response to treatment who
require further interventions to improve outcomes.
Is it safe to base antibiotic decisions on biomarkers? A
large multi-centred, prospective, randomised, controlled,
non-inferiority trial [15, 16] with open intervention per-
formed in Switzerland recruited 1359 patients, and was
designed to examine whether a PCT algorithm can re-
duce antibiotic exposure without increasing the risk for
Fig. 1 Receiver operating characteristics curves (ROC) of different parameters for the diagnosis of pneumonia. a Diagnostic accuracy to predict
CAP without chest radiography: Primary care approach. b Diagnostic accuracy to predict radiographically suspected CAP (control group (n = 20)
includes other non-infectious diagnoses initially diagnosed as CAP): Emergency department approach. c Diagnostic accuracy to predict radiographically
suspected CAP (control group (n = 44) includes other non-infectious diagnoses initially diagnosed as CAP (n = 20) plus patients without a clinically
relevant bacterial aetiology of CAP (n = 24). d Diagnostic accuracy to predict bacteraemic CAP. Values show areas under the ROC curve with 95% CI.
Chest auscult. = abnormal chest auscultation; CRP, C-reactive Protein; PCT, procalcitonin. Sourced from [12]
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lower respiratory tract infections (LRTI) presenting to the
emergency departments were recruited, including patients
with CAP, acute bronchitis and chronic obstructive pul-
monary disease with acute exacerbations. The primary
non-inferiority end point was a 30-day composite of over-
all adverse events including death from any cause, ICU
admission for any reason, disease specific complications
and recurrence of LRTI in need of antibiotics, with or
without hospital readmission. Using predetermined PCT
cut-offs (Fig. 2 [16],) the trial demonstrated an overall ad-
verse outcome similar in the PCT-driven group versus the
control group (15.4% [n = 103] vs. 18.9% [n = 130]; differ-
ence, -3.5%; 95% CI -7.6 to 0.4%). The odds ratio (OR) for
the combined adverse outcome was 0.76 (95% CI 0.57–
1.01). The secondary endpoint of mean duration of anti-
biotic exposure was lower in the PCT group versus the
control group in all patients (5.7 vs. 8.7 days; relativechange, -34.8%; 95% CI -40. to 28.7%) as well as in the
subgroup analysis of patients with CAP (n = 925, 7.2 vs.
10.7 days, 32.4%; 95% CI -37.6 to -26.9%).
As mentioned previously, IFN-γ down-regulates PCT
production, which could help distinguish between viral and
bacterial infections. Algorithms based on PCT values have
been validated to aid in deciding whether patients have bac-
terial CAP versus viral CAP and hence require antibiotics.
The suggestions are identical to those used in the ProHOSP
study above and are as follows: PCT <0.10 mcg/l: strongly
discourage antibiotic use; PCT between 0.10-0.25 mcg/l:
discourage antibiotic use; PCT between 0.25-0.50 mcg/l:
encourage antibiotic use; PCT >0.50 mcg/l: strongly en-
courage antibiotic use [17]. This has been shown to be ef-
fective in studies evaluating LTRI to aid in diagnosis and
decrease antibiotic prescription [17, 18]. A recent study
[19], which evaluated 2259 adults with radiographic evi-
dence of CAP requiring hospitalisation in the United States,
Fig. 2 Antibiotic stewardship based on procalcitonin (PCT) cut-off ranges. Re-evaluation of the clinical status and measurement of serum PCT
levels is mandatory after 6–24 h in all persistently sick and hospitalized patients in who antibiotic are withheld. PCT, procalcitonin; ICU, intensive
care unit. Adapted from [16]
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were able to culture an organism, 530 (23%) had one or
more viruses, 247 (11%) had bacteria, and bacterial and
viral pathogens in were found in 59 (3%), The viral burden
in CAP is often underappreciated and this study illustrates
that PCT may be useful in helping with antibiotic decision
making.
The Cochrane meta-analysis evaluating the use of PCT
to initiate or discontinue antibiotics in LRTI analysed data
from 14 trials with 4221 patients with acute respiratory in-
fections (50% had CAP), including the Swiss cohort. They
demonstrated a reduction in antibiotic exposure (from a
median of 8 to 4 days) [20]. The reduction of antibiotics
used did not impact on outcomes; there was no increase
in mortality or treatment failure in any of the clinical set-
tings it was investigated in (outpatient clinic, emergency
department) or in patients with any type of acute respira-
tory infection, including CAP. This can be seen as a major
gain for antibiotic stewardship programs.
Predicting complications, outcomes and mortality
There now is evidence that biomarkers can be also be
used to predict complications, outcomes and mortality.A recent study performed in Uganda looking at the
usefulness of PCT in HIV-infected individuals with
lower respiratory tract infections to predict in-hospital
mortality is particularly useful. Often HIV-infected and
immunosuppressed patients are excluded from studies;
therefore, one is never sure how to extrapolate the bio-
marker evidence into actual practice, especially if that
practice is in a country with a high HIV prevalence.
Tokmen and colleagues [21] performed a prospective,
nested, case control study on data from the larger
International HIV-associated Opportunistic Pneumo-
nias (IHOP) study, investigating the mortality predict-
ability of PCT in HIV-infected individuals with lower
respiratory tract infections. This study is different from
many of those undertaken before, as it looked at only
HIV-infected individuals and at patients with symptoms
for longer than 2 weeks, therefore looking to include
patients with tuberculosis and Pneumocystis pneumo-
nia (PCP). A cohort of 241 HIV-infected patients had
PCT measurements performed. The cohort had advanced
HIV disease with a median CD4 count of 47 cells/μL.
Unfortunately, a final diagnosis could not be made in
22.8% of the group due to death or inability to follow up;
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tients. As predicted, tuberculosis was the most common
diagnosis at 71.9% (n = 146/203), with bacterial pneumo-
nia second at 12.3% (n = 25/203) and only 1% being PCP
(n = 2/203). The median PCT level was 1.45 ng/ml. The
authors decided to use a cut-off of 0.5 ng/ml for PCT
assessment of mortality prediction. If patients had an ele-
vated PCT (>0.5 ng/ml), it was associated with an in-
creased predicted probability of mortality (1% mortality in
those with PCT ≤ 0.5 ng/ml vs. 10% mortality in those
with a PCT of > 0.5 ng/ml; p = 0.004). This cohort had a
reported in-hospital mortality that was very low and this
could be a confounding factor if the data were extrapo-
lated to other institutions. They performed further data
analysis and found that by combining elevated PCT plus
tachypnoea plus hypoxaemia, the accuracy of in-hospital
mortality prediction resulted in an AUC of 0.741 (95% CI
0.65–0.83). This was a marked improvement compared to
tachypnoea and hypoxaemia without PCT, which had an
AUC of 0.659 (95% CI 0.55–0.77; p = 0.05). It is exciting
that the authors have shown that adding a biomarker to
easily assessable clinical criteria can markedly improve the
ability to predict in-hospital mortality.
Another study [22], from the large Swiss cohort pre-
viously mentioned, evaluated the performance of PCT
as a prognostic indicator, alongside the already vali-
dated CAP scores, the PSI, and the CURB-65 score. The
study of the prognostic potential of PCT was a predefined
secondary end point of the large multicentre Procalcitonin
Guided Antibiotic Therapy and Hospitalisation in Patients
with Lower Respiratory Tract Infections (ProHOSP) study.
A total of 925 patients were included in the analysis. The
median age of patients enrolled was 73 years, with 41%
being female. While this population group would be
appropriate for the developed world, those who practice
in the developing world where the population would
be much younger should take this into consideration.
Survivors had a much lower median PCT level on admis-
sion than non-survivors: 0.44 ug/l (IGR 0.15–2.63 ug/l)
versus 0.83 ug/l (IQR 0.30–5.67 ug/l) (p = 0.02), as did pa-
tients without adverse outcomes versus those with adverse
outcomes: 0.39 ug/l (IQR 0.14–2.2 ug/l) vs. 1.30 ug/l
(IQR 0.38–7.47 ug/l); p < 0.001. This group did not find
that PCT improved the AUC to predict morality (AUC
0.60), and was in fact lower than the clinical risk scores
alone (AUC CURB-65 = 0.72; AUC PSI = 0.79). Even
when PCT was added to the PSI and CURB-65 clinical
scores, it did not significantly improve either for mor-
tality prediction. However, for prediction of adverse
events combining the PCT with either the CURB-65 or
PSI improved the ability to predict these events better
than the clinical scores alone (PSI plus PCT AUC = 0.71
[0.66–0.76], p < 0.01; CURB-65 plus PCT AUC = 0.70
[0.65–0.75], p = 0.008). This group also found that thefollow up PCT levels measured on day 3, 5 and 7 were
able to provide information about increased risk of
mortality and adverse events in a very similar fashion
to the Coelho group [17]. Those patients who did not
show a clear decrease of PCT had worse outcomes.
Skouras and colleagues [23] used the biomarker CRP to
evaluate its clinical utility as a predictor in parapneumonic
effusions (PPE). It has been estimated that approximately
40% of CAP can be associated with a PPE, most of which
are inconsequential [24]. Up to 7.2% of CAP patients can
go on to develop complicated parapneumonic effusions
(CPPE) or empyema [25]. This is a significant burden in
CAP patients and having the ability to predict or be aware
of patients who are likely to develop this complication
would be very useful. This was a prospective study from
two tertiary Greek hospitals and 54 patients were in-
cluded. Whilst this a small sample size, there is very little
evidence-based medicine in this field. The cohort was
evaluated in 2 groups, those with uncomplicated PPE and
those with CPPE. Admission serum and pleural CRPs
were compared in these 2 groups, as well as residual
pleural thickening 6 months after hospital discharge.
Residual pleural thickening can result in restrictive pul-
monary disease. This study did demonstrate that an ele-
vated serum CRP of >150 mg/l had a sensitivity of 61%
and specificity of 91%, with a ROC of 0.82, for predicting
residual pleural thickening post-PPE. The higher CRP
levels are a marker of a more exuberant inflammatory res-
ponse, which could explain the greater risk for pleural
thickening. This finding adds a useful and easy test to
allow for identification of patients who are at risk for
long-term complications from PPE. Serum CRP and
pleural CRP were significantly higher in CPPE. ROC
curves evaluating accuracy to identify CPPE were 0.73 for
pleural CRP and 0.68 for serum CRP, compared to the
ROC of the more traditionally used low pleural fluid pH
(pH < 7.1) of 0.93. Therefore, by themselves these tests are
clearly inferior to tests used in current clinical practice.
However, when combined with the classical criteria using
an ‘AND’ or ‘OR’ rule, the positive and negative predictive
values for diagnosis of a CPPE were improved. The
group concluded that the serum CRP has value as an
independent predictor for the development of residual
pleural thickening. They also showed that it could be
used in combination with the more traditional bio-
markers—pleural fluid LDH, glucose and pH—to help
with treatment decisions in non-purulent PPE.
The future
The biomarker of the future will most likely be pro-
adrenomedullin (pro-ADM). Adrenomedullin (ADM) is
produced at times of physiologic stress and has vasodila-
tory, antimicrobial, and anti-inflammatory properties. As
early as 1996, Hirata and colleagues showed that levels
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sepsis [26]. However ADM is not an ideal biomarker as
it is rapidly cleared from circulation due to its rapid
binding to receptors and its half-life of 22 min, so
midregional-proadrenomeddullin (MR-proADM), a more
stable precursor molecule, is used in clinical practice.
There have been several studies that have shown that
MR-proADM has better predictive power than even
CRP and PCT. In a prospective cohort study of 491 pa-
tients with CAP, admission MR-proADM levels correlated
with and improved clinical severity scores [27]. Studies by
Christ-Crain et al. and Kruger et al. both demonstrated
the improved mortality prediction of MR-proADM when
added to the PSI [28, 29]. A systematic review, which in-
cluded twelve studies, evaluated the prognostic value of
MR-proADM in short and long term mortality in CAP.
The authors demonstrated an increase in short-term mor-
tality (OR = 6.8; 95% CI: 4.65–10.13; p < 0.001) and com-
plications (OR = 5.0; 95% CI: 3.86–6.49; p < 0.001) with
elevated MR-proADM. A further pooled analysis of 4 of
the studies showed an improved discriminant ability for
predicting mortality in CAP patients of 8% (95% CI: 2–
14%) when MR-proADM was added to the CURB-65/
CRB-65 score [30]. When this test becomes more com-
mercially available, there will be another important tool
for CAP outcome prediction.
Further fascinating work has recently been done to
identify a novel biomarker in CAP by analysis of the
blood genomic response in CAP patients. Global gene
expression profiles of whole blood leukocytes were col-
lected within 24 h after ICU admission from CAP and
non-CAP patients and then compared with those of
healthy individuals [31]. A 78-gene signature was defined
for CAP and the FAIM3:PLAC8 gene expression ratio was
derived with an AUC of 0.845 (95% CI, 0.764–0.917) and
positive and negative predictive values of 83 and 81%,
respectively, when looking at ability to diagnosis CAP.
Interestingly FAIM3, encoding the FAS apoptotic inhibi-
tory molecule 3, and PLAC8, encoding placenta-specific 8,
are both negative regulators of apoptosis. The FAIM3:
PLAC8 ratio outperformed plasma procalcitonin and IL-8
and IL-6 in discriminating between CAP and non-CAP
patients. Studies looking at gene expression in CAP, such
as the above by Scicluna and colleagues, are not only about
biomarkers but also add information to the understanding
of the pathophysiology of the immune response in CAP.
Another up and coming approach to the biomarker field
is that of metabolomics. Metabolomics is the investigations
of the biochemical molecules derived from cellular pro-
cesses, and it is studied under specific conditions, including
CAP [32]. An example of metabolomics application in CAP
is kynurenine (Kyn). Kyn is a toxic metabolite formed
during the degradation of tryptophan (Trp), and patients
with CAP and sepsis show significantly higher Kyn levelsand lower Trp levels compared to controls [33, 34]. A more
familiar metabolomic example, which has been used in
critical care for prognosis and severity, is lactate. In adults
with pneumonia, the lactate level has been shown to be a
better predictor of 28-day mortality than the CURB-65
score, and a combination of CURB-65 with lactate level im-
proves the predictive value of CURB-65 score alone [35].
For further reading Nickler and colleagues have written an
interesting review article looking at this growing field
and its impact on our understanding of respiratory
conditions [32].
Conclusion
Point-of-care tests are now available, making it possible
to utilise knowledge about biomarkers, even in the
emergency room and doctor’s room setting. Clinicians
can make real-time decisions about the care and the
admission path of patients. Once there is a complete
understanding of all the information that can be gained
from these simple tests, there will be greater insight
into the future management of patients with CAP. This
is especially true with regards to predicting complica-
tions and outcomes and, most importantly, response to
treatment and earlier discontinuation of antibiotics.
Hopefully, in the future, the benefits of implementing
what is known about biomarkers will be reflected in
improved patient outcomes.
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